Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

As pivotal data on the new generation of anticoagulants continue to become public, differences in trial design and population are confusing attempts to predict competitive positioning for the new agents.

You may also be interested in...

Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track

FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.

Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard

Pradaxa, the Boehringer Ingelheim drug that FDA approved on Oct. 19, is the first of several oral anti-coagulants that could come on the U.S. market near-term and shake up existing standards of care.

FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority

The pivotal issue remaining for FDA's review of Boehringer Ingelheim's Pradaxa (dabigatran) is whether it will clear both the 110 mg and 150 mg doses and how it can craft labeling to guide appropriate use toward the higher dose, which seems likely to gain a superiority claim over warfarin.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts